+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Guillain-Barre Syndrome Market by Treatment Type (Corticosteroids, Intravenous Immunoglobulin, Plasmapheresis), Product Type (Devices, Pharmaceuticals), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Guillain-Barre Syndrome Market by Treatment Type (Corticosteroids, Intravenous Immunoglobulin, Plasmapheresis), Product Type (Devices, Pharmaceuticals), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Guillain-Barre Syndrome Market by Treatment Type (Corticosteroids, Intravenous Immunoglobulin, Plasmapheresis), Product Type (Devices, Pharmaceuticals), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715770
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Guillain-Barré Syndrome (GBS) Market is marked by steady growth and dynamic transformation, driven by evolving clinical needs, advancing therapeutic modalities, and increasing operational complexities across global healthcare systems. Senior decision-makers in healthcare, pharmaceuticals, and medtech are increasingly prioritizing targeted investments and collaborations that address patient-centric outcomes in this multifaceted landscape.

Market Snapshot: Guillain-Barré Syndrome Market at a Glance

The Guillain-Barré Syndrome Market grew from USD 665.39 million in 2024 to USD 676.51 million in 2025. It is expected to continue growing at a CAGR of 1.65%, reaching USD 734.36 million by 2030. This positive trajectory reflects rising clinical awareness, improvements in diagnosis, and technology-driven care models. Market expansion is influenced by innovations in immunoglobulin therapies, apheresis technology, and the adoption of digital health in post-acute GBS management. Global supply chains and region-specific regulatory developments further shape procurement and access trends.

Scope & Segmentation of the Guillain-Barré Syndrome Therapeutics Market

  • Treatment Type: Corticosteroids, intravenous immunoglobulin (including 10% and 5% concentrations, as well as subcutaneous forms), plasmapheresis, and supportive therapies.
  • Product Type: Devices such as apheresis machines and disposable kits, and pharmaceuticals including corticosteroids and immunoglobulin concentrates.
  • Route of Administration: Intravenous (central and peripheral), subcutaneous (clinic and home-based use).
  • Distribution Channel: Hospital pharmacy, online pharmacy, and retail pharmacy.
  • End User: Home healthcare (home infusion and telemedicine services), hospitals (private and public), specialty clinics (neurology clinics and rehabilitation centers).
  • Regions Covered: Americas (with detail for United States states such as California, Texas, New York, and others), Canada, Mexico, Brazil, Argentina; Europe, Middle East & Africa (including UK, Germany, France, and several other countries); Asia-Pacific (covering China, India, Japan, Australia, and more).
  • Leading Companies Profiled: CSL Limited, Grifols S.A., Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A., Biotest AG, LFB Groupe Bioproduction, Sandoz International GmbH, Fresenius Kabi AG, Bio Products Laboratory Limited.

Key Takeaways for Senior Decision-Makers

  • Early adoption of molecular diagnostics and advanced biomarkers is shifting clinical practice, enabling faster identification and personalized management of GBS cases.
  • Subcutaneous immunoglobulin formulations and portable apheresis technologies are decentralizing care delivery, facilitating outpatient management and supporting home healthcare models.
  • Strategic collaborations between pharmaceutical manufacturers and device companies are fostering innovation in both biologic therapies and user-friendly therapeutic devices.
  • Outcome-based reimbursement contracts are aligning stakeholder incentives, with a growing emphasis on patient-reported outcomes and long-term functional recovery.
  • Regulatory authorities are increasingly supporting adaptive clinical trial designs and expedited approvals to address emergent unmet clinical needs.
  • Regional disparities in treatment access and reimbursement are influencing distribution models, requiring adaptable go-to-market strategies for global and local stakeholders alike.

Tariff Impact: Navigating Supply Chain Disruptions and Access Risks

The 2025 introduction of new U.S. tariffs has impacted costs across GBS therapeutic supply chains. Tariffs on single-use apheresis kits and immunoglobulin excipients have led manufacturers to pursue contract renegotiations, investment in nearshore production, and vertical integration for raw material security. These responses, while necessary, introduce temporary supply disruptions and raise the importance of coordinated procurement strategies. Healthcare networks are mitigating risks by utilizing group purchasing organizations and diversifying treatment modalities, such as increased use of subcutaneous immunoglobulin to reduce reliance on tariff-affected intravenous therapies. Maintaining robust quality assurance and compliance remains essential amid cost containment efforts.

Methodology & Data Sources

This analysis integrates comprehensive secondary research with direct engagement of industry experts. Peer-reviewed studies, clinical trial registries, and regulatory filings informed treatment landscape mapping, while consultations with clinicians and supply chain specialists provided real-world perspectives. Multiple data points were cross-validated, and scenario modeling evaluated supply chain resiliency in fluctuating tariff and demand environments.

Why This Report Matters: Actionable Insights for Senior Leaders

  • Empowers leadership teams to make informed investments and partnership choices for staying competitive within the evolving GBS therapeutics ecosystem.
  • Supports operational planning by highlighting emerging risks, technology-driven care models, and region-specific dynamics that influence access and outcomes.

Conclusion

This report delivers a strategic lens on the future of Guillain-Barré Syndrome therapeutics. By aligning clinical, operational, and regulatory advances, stakeholders can strengthen patient care and enhance resilience amid changing global conditions.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing clinical trial activity for complement inhibitors targeting refractory Guillain-Barre syndrome
5.2. Expanding use of telehealth and digital rehabilitation platforms to support post-GBS patient recovery
5.3. Growing demand for rapid diagnostic assays and biomarker panels for early Guillain-Barre syndrome detection
5.4. Heightened scrutiny of post-vaccination Guillain-Barre syndrome incidence influencing regulatory policies
5.5. Emergence of home infusion services for intravenous immunoglobulin therapy improving patient adherence rates
5.6. Strategic market entry by biosimilar developers targeting high-cost immunoglobulin products in GBS treatment
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Guillain-Barre Syndrome Market, by Treatment Type
8.1. Introduction
8.2. Corticosteroids
8.3. Intravenous Immunoglobulin
8.3.1. 10% Immunoglobulin
8.3.2. 5% Immunoglobulin
8.3.3. Subcutaneous Immunoglobulin
8.4. Plasmapheresis
8.5. Supportive Therapies
9. Guillain-Barre Syndrome Market, by Product Type
9.1. Introduction
9.2. Devices
9.2.1. Apheresis Machines
9.2.2. Disposable Kits
9.3. Pharmaceuticals
9.3.1. Corticosteroids
9.3.2. Intravenous Immunoglobulin
10. Guillain-Barre Syndrome Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.2.1. Central Venous Administration
10.2.2. Peripheral Venous Administration
10.3. Subcutaneous
10.3.1. Clinical Setting
10.3.2. Home Infusion
11. Guillain-Barre Syndrome Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Guillain-Barre Syndrome Market, by End User
12.1. Introduction
12.2. Home Healthcare
12.2.1. Home Infusion
12.2.2. Telemedicine Services
12.3. Hospitals
12.3.1. Private Hospitals
12.3.2. Public Hospitals
12.4. Specialty Clinics
12.4.1. Neurology Clinics
12.4.2. Rehabilitation Centers
13. Americas Guillain-Barre Syndrome Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Guillain-Barre Syndrome Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Guillain-Barre Syndrome Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. CSL Limited
16.3.2. Grifols, S.A.
16.3.3. Takeda Pharmaceutical Company Limited
16.3.4. Octapharma AG
16.3.5. Kedrion S.p.A.
16.3.6. Biotest AG
16.3.7. LFB, Groupe Bioproduction
16.3.8. Sandoz International GmbH
16.3.9. Fresenius Kabi AG
16.3.10. Bio Products Laboratory Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GUILLAIN-BARRE SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GUILLAIN-BARRE SYNDROME MARKET: RESEARCHAI
FIGURE 26. GUILLAIN-BARRE SYNDROME MARKET: RESEARCHSTATISTICS
FIGURE 27. GUILLAIN-BARRE SYNDROME MARKET: RESEARCHCONTACTS
FIGURE 28. GUILLAIN-BARRE SYNDROME MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GUILLAIN-BARRE SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 10% IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 10% IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 5% IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY 5% IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY APHERESIS MACHINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY APHERESIS MACHINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISPOSABLE KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISPOSABLE KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CENTRAL VENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CENTRAL VENOUS ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PERIPHERAL VENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PERIPHERAL VENOUS ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CLINICAL SETTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY CLINICAL SETTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TELEMEDICINE SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TELEMEDICINE SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 153. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 154. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 155. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 156. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 157. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 158. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 159. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 160. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 161. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 162. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 163. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 166. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 167. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 168. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 169. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 174. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 175. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 176. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 177. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 178. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 179. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 180. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 181. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 182. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 183. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 186. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 187. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 188. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 189. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 194. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 195. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 200. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 201. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 202. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 203. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 204. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DEVICES, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHARMACEUTICALS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOME HEALTHCARE, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 311. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 312. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 313. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
TABLE 314. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULIN, 2025-2030 (USD MILLION)
TABLE 315. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (US

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Guillain-Barre Syndrome market report include:
  • CSL Limited
  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • Biotest AG
  • LFB, Groupe Bioproduction
  • Sandoz International GmbH
  • Fresenius Kabi AG
  • Bio Products Laboratory Limited

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 676.51 Million
Forecasted Market Value ( USD ) by 2030 $ 734.36 Million
Compound Annual Growth Rate1.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutic (Intravenous Immunoglobulin (IVIG)), By Type (AIDP), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 130 Pages
  • Global
From
Guillain-Barre Syndrome Therapeutics - Global Strategic Business Report - Product Image

Guillain-Barre Syndrome Therapeutics - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Guillain-Barre Syndrome Drugs: Market Share, and Growth Analysis by Product Type (Immunoglobulin Therapy, Plasma Exchange, Corticosteroids), Application, End User, Technology - Product Image

Guillain-Barre Syndrome Drugs: Market Share, and Growth Analysis by Product Type (Immunoglobulin Therapy, Plasma Exchange, Corticosteroids), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Guillain-Barre Syndrome Drugs Market Report 2025 - Product Image

Guillain-Barre Syndrome Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Guillain-Barre Syndrome (GBS) Epidemiology Forecast 2025-2034 - Product Image

Guillain-Barre Syndrome (GBS) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From

About the Guillain Barre Syndrome Drug Market

The Guillain Barre Syndrome Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat Guillain Barre Syndrome, a rare autoimmune disorder that affects the peripheral nervous system. The drugs used to treat this disorder are typically immunomodulatory agents, such as intravenous immunoglobulin, plasma exchange, and corticosteroids. These drugs are used to reduce inflammation and suppress the immune system, allowing the body to recover from the disorder. The Guillain Barre Syndrome Drug market is highly competitive, with many companies offering treatments for the disorder. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Other companies, such as Biogen, AbbVie, and Johnson & Johnson, also offer treatments for the disorder. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.